Ani Pharmaceuticals (ANIP) FCF Margin (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted FCF Margin of 22.02% for Q1 2026, up 29.84% sequentially from 16.96% in Q4 2025, and up 479.0% YoY from 3.8% in Q1 2025.
Ani Pharmaceuticals (ANIP) FCF Margin (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported FCF Margin for 17 years, with the latest figure at 22.02% in Q1 2026.
- Quarterly FCF Margin rose 479.0% year-over-year to 22.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.92% (up 999.0% YoY) and the FY2025 annual result came in at 20.85%, up 1052.0% from the prior year.
- FCF Margin advanced to 22.02% in Q1 2026 per ANIP's latest filing, from 16.96% in the prior quarter.
- Over five years, FCF Margin peaked at 33.92% in Q4 2023 and troughed at 29.77% in Q1 2022.
- A 5-year average of 11.51% and a median of 15.55% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin tumbled 20807 bps in 2022, then surged 4763 bps in 2023.
- Over 5 years, FCF Margin stood at 4.93% in 2022, then jumped by 788 bps to 33.92% in 2023, then tumbled by 55 bps to 15.31% in 2024, then rose by 11 bps to 16.96% in 2025, then climbed by 30 bps to 22.02% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 22.02%, 16.96%, and 16.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn | 20.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.15% |
| Mar 31, 2026 | 22.02% |
| Dec 31, 2025 | 16.96% |
| Sep 30, 2025 | 16.66% |
| Jun 30, 2025 | 33.28% |
| Mar 31, 2025 | 17.23% |
| Dec 31, 2024 | 15.31% |
| Sep 30, 2024 | 0.17% |
| Jun 30, 2024 | 12.33% |
| Mar 31, 2024 | 12.40% |
| Dec 31, 2023 | 33.92% |
| Sep 30, 2023 | 27.89% |
| Jun 30, 2023 | 15.55% |
| Mar 31, 2023 | 17.86% |
| Dec 31, 2022 | -4.93% |
| Sep 30, 2022 | 5.01% |
| Jun 30, 2022 | -16.26% |
| Mar 31, 2022 | -29.77% |
| Dec 31, 2021 | -20.20% |
| Sep 30, 2021 | -7.30% |